A grocery store pharmacy is supposed to be one of the last safety checks before a prescription reaches a patient. According to a Washington judge, Albertsons bypassed that safeguard millions of times, and it must now pay $900 million for its role in the state’s opioid crisis.

On Nov. 5, King County Superior Court Judge Janet Helson ruled that the grocer substantially contributed to Washington’s opioid epidemic by repeatedly filling suspicious prescriptions across its more than 200 Albertsons, Safeway and Haggen pharmacies, Reuters reported.

Here’s what the court found, why pharmacists share legal responsibility for the prescriptions they fill and what the historic verdict could mean for families and communities navigating addiction.

Why was Albertsons ordered to pay $900 million over the opioid crisis?

Washington’s attorney general first filed the Albertsons opioid lawsuit in 2022, along with suits against other major pharmacy chains. Kroger later settled with the state for $47.5 million, according to the Washington State Standard. Albertsons, however, went to trial.

After a nine-week, non-jury trial, Helson issued a 218-page ruling. In it, she wrote that the state “is in the throes of an opioid epidemic that is so wide-reaching and damaging that it has impacted Washingtonians throughout the state.”

Specifically, she found that Albertsons violated the state’s consumer protection law and contributed to a public nuisance. Attorney General Nick Brown called it “a victory for the people of the state of Washington.” Notably, he said it is believed to be the largest verdict in state history.

What did Albertsons pharmacies do wrong when dispensing opioid prescriptions?

Above all, the core finding centers on red flags. These are warning signs that a prescription might not be for a legitimate medical purpose or could be diverted to illegal use.

Between 2006 and 2022, Albertsons pharmacies filled opioid prescriptions more than 6.5 million times despite red flags, without documenting efforts to resolve those concerns, according to the Washington attorney general’s office. Over that same period, the company dispensed more than 641 million opioid pills in the state. Strikingly, 96% of those red-flagged prescriptions lacked documentation showing the concern had been adequately resolved, according to the court’s findings.

For example, common red flags include:

  • Unusually large quantities or high doses of opioids.
  • The same drug, dose and directions written for many patients by one prescriber.
  • Dangerous combinations, such as an opioid with a benzodiazepine and a muscle relaxant.
  • Patients traveling long distances or using several prescribers and pharmacies.
  • Prescriptions from doctors with known patterns of problematic prescribing.

In addition, Helson found that Albertsons “failed to meaningfully prevent the dispensing of opioid prescriptions written by pill mill doctors,” according to the ruling. The company dispensed more than 5.5 million pills to patients of five of those prescribers, all of whom later had their licenses suspended.

The red flags pharmacists watch for

Pharmacists know these warning signs well. “Common red flags include paying cash to avoid insurance tracking, traveling long distances to fill a prescription, repeated early-fill requests, overlapping opioid prescriptions from multiple prescribers, unusually high doses or quantities, signs that the prescription was altered or forged, and prescribing outside a practitioner’s usual scope of practice,” Jamie Winn, PharmD, a pharmacist and medical director at the online pharmacy Universal Drugstore, told Blavity Health.

Workload can make those signs harder to catch. “These pressures do not remove the pharmacist’s responsibility, but they can increase the risk of a fraudulent or illegitimate prescription slipping through,” Winn said.

Why are pharmacists responsible for identifying suspicious opioid prescriptions?

Many people assume a pharmacist simply fills whatever a doctor writes. In reality, however, federal law asks more of them.

Under federal regulations, the doctor who writes a controlled substance prescription is responsible for making sure it is legitimate. However, “a corresponding responsibility rests with the pharmacist who fills the prescription,” according to 21 CFR 1306.04. In other words, pharmacists share the duty to make sure a prescription serves a real medical purpose.

So, a valid-looking prescription from a licensed physician does not end the pharmacist’s job. When a red flag appears, the pharmacist must look into it, resolve it and document what they did. If they cannot resolve it, they should not fill the prescription.

That said, courts have debated how far this duty extends. In February 2026, for example, the Fifth Circuit Court of Appeals narrowed how the DEA can use red flags to prove a pharmacist violated the rule, according to a legal analysis on JD Supra. The Washington judge, by contrast, ruled under state law.

How did Albertsons’ pharmacy policies contribute to the opioid crisis?

Importantly, the judge’s findings in the Albertsons opioid lawsuit went beyond individual prescriptions. Instead, they focused on how the company ran its pharmacies.

According to the ruling, Albertsons failed to adequately staff its pharmacies and did not properly train pharmacists on dispensing controlled substances. It also “failed to establish an adequate compliance department to ensure the proper dispensing of controlled substances,” Helson wrote.

Moreover, the company tied pharmacy staffing to prescription counts. Helson found that its “overall emphasis on prescription volume,” combined with understaffing, “contributed to an environment in which inappropriate dispensing occurred.”

Frontline pharmacists felt that pressure firsthand. The ruling cites complaints from pharmacy staff. One manager described “working 12-hour shifts (for the pharmacist) without breaks.” Another pharmacist told Albertsons’ CEO, “99% of the days I do not even get to eat, and sometimes I don’t even get to use the bathroom.”

Notably, Helson did not find “that there was evidence that pharmacists intentionally dispensed improperly in order to increase profits.” Instead, she pointed to the company’s “overall prioritization of profits combined with failure to provide pharmacists necessary tools and sufficient staffing.”

Ultimately, Helson concluded that the company chose business over safety. “Albertsons possessed, but routinely disregarded or ignored, information and tools that could have helped prevent diversion, choosing sales and profits over patient safety,” the ruling states.

For its part, Albertsons argued at trial that its pharmacies “are a mirror of what the doctors are doing.” Helson rejected that defense, writing that a pharmacist who simply mirrors prescribers “is effectively abdicating his or her corresponding responsibility.”

How will the $900 million Albertsons opioid judgment be used?

The judgment has two parts, according to the ruling. First, $800 million goes toward abatement, meaning money to address the damage the epidemic has caused. Second, Albertsons must pay $100 million in civil penalties, plus the state’s attorneys’ fees and costs.

Notably, the state had asked for much more. At trial, Washington requested $2.2 billion for abatement alone, the ruling states.

The state says the money will help expand treatment and prevention. In a statement, Brown said the verdict “will provide desperately needed resources to support treatment and prevent future crises.”

Clinicians say the best use of that money is clear. “The proven method of saving lives from fentanyl overdose is to make addiction treatment more accessible, and addiction medications like buprenorphine and methadone very easy to obtain via prescription and a pharmacy fill,” Aleksey Aronov, AGPCNP-BC, a board-certified adult-gerontology primary care nurse practitioner in New York, told Blavity Health. He also called for funding housing and recovery coaching “so they stay on their treatment continuously.”

The ruling also permanently requires Albertsons to resolve and document every red flag before filling an opioid prescription in Washington. Pharmacists must check the state’s prescription monitoring program, and stores must have enough staff to do that review. For five years, a company officer must certify compliance under oath each year.

Why is Washington’s Albertsons opioid lawsuit separate from the national settlement?

In April 2026, Albertsons reached an agreement to settle most opioid claims brought against it by states, local governments and other groups nationwide, Grocery Dive reported. Reports differ on the exact amount. California’s attorney general put the deal at up to $773.8 million, while other outlets, including KNKX, have cited $776 million. Washington chose not to join.

Instead, the state bet that a trial would bring more accountability. “We thought the liability and the accountability that we needed to achieve against Albertsons was greater than the efforts that we were seeing elsewhere,” Brown said, OPB reported. For now, that bet appears to have paid off.

In fact, the verdict brings Washington’s total opioid recoveries to $2.17 billion for state and local governments, according to the attorney general’s office.

How has the opioid epidemic affected Washington communities?

More than 26,000 Washingtonians have died from opioid overdoses since 1999, according to the attorney general’s office. Over the last three years alone, more than 7,400 residents died, KUOW reported.

Still, the damage reaches far beyond those deaths. Helson wrote that the crisis has decreased public safety, increased criminal justice costs and strained local governments and law enforcement. Families, emergency rooms and treatment programs also carry the weight.

Nationally, the epidemic came in waves. It began with prescription opioids in the 1990s, then shifted to heroin and later to illegally made fentanyl, according to the CDC. Meanwhile, Black communities have been hit hard in recent years. From 2019 to 2020, overdose death rates rose 44% among Black people, one of the largest increases of any group, CDC researchers found.

Still, experts caution against oversimplifying that path. “That was one pathway into today’s crisis, but it was never everyone’s story. Physical dependence alone does not mean addiction, and many people now encounter fentanyl without ever having used prescription opioids,” Tanveer A. Padder, MD, a triple board-certified psychiatrist in psychiatry, addiction medicine and clinical psychopharmacology and founder of OnDemand Psychiatry, told Blavity Health.

At the same time, stricter opioid checks must not shut out people with real pain. Research has found that racial bias affects pain treatment, with Black patients’ pain more likely to be underestimated and undertreated, according to a study in PNAS. Good pharmacy safeguards should catch diversion without blocking legitimate care.

How families can spot opioid use disorder

Early warning signs are often easy to miss. “Families most often miss the beginning of an opioid addiction because they’re looking for a dramatic sign but what actually happens first is a change in patterns,” Megan Goldberg, LICSW, a Washington, D.C.-based clinical social worker who treats addiction and trauma, told Blavity Health. Those changes can include slow replies to calls and texts, constant tiredness or canceled plans.

Instead of staging a surprise intervention, Goldberg recommends starting small. “It works best when one person has a private conversation where they name something concrete they’ve noticed and share that they’re worried,” she said.

Also, know what to do in an emergency. Signs of an overdose include extreme sleepiness, slow or absent breathing, blue lips and pinpoint pupils. “Family should then immediately provide naloxone and call 911. It is also very important to remain with the loved one, even after giving naloxone as they may require additional doses because it is short acting medication and does not stay in the system long,” Cooper Stone, DO, a clinical assistant professor of psychiatry at the University of Pennsylvania, told Blavity Health.

How to protect yourself and your family from opioid harm

  • Keep naloxone on hand: Naloxone nasal spray is available over the counter and can reverse an opioid overdose, according to the FDA.
  • Store opioids securely: Lock up prescription pain medicines and count pills regularly.
  • Dispose of leftovers safely: Use a pharmacy take-back kiosk or a community take-back event.
  • Ask questions: If your pharmacist asks about your prescription, they are doing their job. Answer openly and ask about risks.
  • Get help 24/7: Call SAMHSA’s free, confidential National Helpline at 1-800-662-4357 for treatment referrals.

What happens next in the Albertsons opioid lawsuit?

Still, the ruling may not be the final word in the Albertsons opioid lawsuit. Albertsons said it is “disappointed by the court’s ruling and respectfully disagrees with its conclusions.” Moreover, the company said it is considering an appeal, which could delay payment for months or even years. It could also reduce the final amount, depending on how a higher court views the ruling. As a result, it’ll take a while for the $900 million to reach Washington, the Washington State Standard reported.

Meanwhile, the case adds to a broader reckoning. Opioid lawsuits nationwide have produced settlements now totaling roughly $58 billion, according to Reuters. Still, Washington’s verdict stands out because it came from a full trial rather than a negotiated deal.

Bottom line

In the Albertsons opioid lawsuit, a Washington judge ordered the company to pay $900 million after finding its pharmacies filled millions of red-flagged opioid prescriptions without proper checks. The judge earmarked most of the money to fight the opioid crisis, but an appeal could delay or reduce it. For families, the case is a reminder that pharmacists are an important safety check and that naloxone and treatment are available now.

Frequently Asked Questions

Can a pharmacist refuse to fill a doctor’s prescription for opioids?

Yes, because pharmacists share a “corresponding responsibility” to fill only controlled substance prescriptions issued for a legitimate medical purpose, according to federal regulations.

Will people affected by the opioid crisis receive money from the Albertsons settlement?

Generally no, because the $800 million abatement award is meant to fund treatment, prevention and other statewide efforts rather than individual payments, according to Reuters.

Citations

KNKX. Washington wins $900 million verdict in Albertsons opioid trial. KNKX Public Radio. Published November 7, 2026. https://www.knkx.org/public-health/2026-11-07/washington-wins-verdict-albertsons-opioid-trial-nick-brown

Attorney General Rob Bonta Announces $773 Million Agreement in Principle with Albertsons for its Role in Opioid Epidemic. California Department of Justice. Published April 14, 2026. https://oag.ca.gov/news/press-releases/attorney-general-bonta-announces-773-million-agreement-principle-albertsons-its

Washington wins $900 million verdict against Albertsons for fueling opioid crisis. Washington State Office of the Attorney General. Published November 5, 2026. https://www.atg.wa.gov/news/news-releases/washington-wins-900-million-verdict-against-albertsons-fueling-opioid-crisis

KUOW. Washington vs. Albertsons trial begins over grocery giant’s alleged role in opioid crisis. KUOW. Published July 13, 2026. https://www.kuow.org/law/2026-07-13/washington-vs-albertsons-trial-begins-over-grocery-giants-alleged-role-in-opioid-crisis

Centers for Disease Control and Prevention. Understanding the Opioid Overdose Epidemic. CDC. Accessed November 9, 2026. https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html

Electronic Code of Federal Regulations. 21 CFR 1306.04, Purpose of issue of prescription. National Archives. Accessed November 9, 2026. https://www.ecfr.gov/current/title-21/section-1306.04

Goldstein-Street J. Albertsons must pay $900M for role in WA opioid crisis, judge rules. Washington State Standard. Published November 5, 2026. https://washingtonstatestandard.com/2026/11/05/albertsons-must-pay-900m-for-role-in-wa-opioid-crisis-judge-rules/

Goldstein-Street J. Albertsons must pay $900M for role in Washington opioid crisis, judge rules. OPB. Published November 6, 2026. https://www.opb.org/article/2026/11/06/albertsons-opioid-washington-drugs-addiction/

Grocery Dive. Albertsons must pay $900M in Washington state opioid case. Grocery Dive. Published November 2026. https://www.grocerydive.com/news/albertsons-washington-state-opioid-case-grocery/873958/

Harris Beach Murtha. Fifth Circuit Limits DEA Use of Red Flags in Pharmacist Liability. JD Supra. Published 2026. https://www.jdsupra.com/legalnews/fifth-circuit-limits-dea-use-of-red-5177353/

Helson JM. State of Washington v. Albertsons Companies, Inc., et al.: Findings of Fact, Conclusions of Law and Order. King County Superior Court. Published November 5, 2026. https://agportal-s3bucket.s3.us-west-2.amazonaws.com/Consumer%20Protection/808_FOFCOL.pdf?VersionId=hHb1IGbBhLyqShncHduEJlrcd3pp6T1b

Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proceedings of the National Academy of Sciences. 2016;113(16):4296-4301. https://doi.org/10.1073/pnas.1516047113

Kariisa M, Davis NL, Kumar S, et al. Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics, 25 States and the District of Columbia, 2019-2020. MMWR. 2022;71(29):940-947. https://doi.org/10.15585/mmwr.mm7129e2

Reuters. Albertsons must pay $900 million for fueling opioid epidemic in Washington state, judge rules. Reuters. Published November 5, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/albertsons-must-pay-900-million-fueling-opioid-epidemic-washington-state-judge-2026-11-05/

Substance Abuse and Mental Health Services Administration. SAMHSA’s National Helpline. SAMHSA. Accessed November 9, 2026. https://www.samhsa.gov/find-help/helplines/national-helpline

U.S. Food and Drug Administration. FDA Approves First Over-the-Counter Naloxone Nasal Spray. FDA. Published March 29, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray